Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

What is the purpose of this trial?

This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Monoclonal antibodies, such as pembrolizumab, may block tumor or cancer growth in different ways by targeting certain cells. It may also help the immune system kill cancer cells.



Cancer Immunotherapy Trials Network

Start Date: 03/09/2017

End Date: 04/01/2018

Last Updated: 02/22/2018

Study HIC#: 1603017496

Get Involved

For more information about this study, contact:
Neta Shanwetter Levit
+1 203-737-6247
neta.shanwetterlevit@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Mario Sznol

Principal Investigator

Sub-Investigators